Combined chemical modified endomorphin-1 and method for preparing same

An endomorphin and peptide fragment technology, which is applied in the field of combinatorial chemically modified endomorphin-1 and its preparation, can solve the problems of rare analgesic analogs, short analgesic duration, poor enzymatic stability, etc. It can improve the physical and chemical properties, prolong the analgesic effect, and improve the stability of enzymatic hydrolysis.

Active Publication Date: 2010-09-08
LANZHOU UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, EM-1 also has disadvantages similar to other endogenous opioid peptides, such as short duration of analgesia, lack of oral activity, poor enzymatic stability, rapid degradation in blood and brain, and short half-life. The presence of the BBB also hinders their access to the CNS to exert their effects, thus limiting the use of endomorphins as therapeutic drugs
Although many endomorphin analogues have been synthesized so far, there are few analogues that can be injected into the CNS to produce analgesia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined chemical modified endomorphin-1 and method for preparing same
  • Combined chemical modified endomorphin-1 and method for preparing same
  • Combined chemical modified endomorphin-1 and method for preparing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Embodiment 2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is four analogs of endomorphin-1, [GMLPC]-FM-1, [GMLDC]-EM-1, [GMDPC]-EM-1 and [GMDDC]-EM-1, prepared through liquid phase synthesis and their preparation process. Serial pharmacological activity identifying measurements shows that these four analogs have enzymolysis stability in brain plasmalemma and blood serum of mouse obviously higher than their precursor, longer pain relieving time, and higher integral liposolubility. The present invention is significant for developing endomorphin-1 into clinical polypeptide analgesic.

Description

technical field The present invention relates to a new class of analogs [GMLPC]-EM-1, [GMLDC]-EM-1, [GMDPC]-EM-1 and [GMDDC] of endomorphin-1 (Endomorphin-1, EM-1) ]-EM-1 and its preparation method. Background technique Endomorphin 1 (Tyr-Pro-Trp-Phe-NH 2 , EM-1) and endomorphin 2 (Tyr-Pro-Phe-Phe-NH 2 , EM-2) are two endogenous opioid peptides that selectively agonize mu opioid receptors with high efficiency. Studies have found that endomorphins can participate in the regulation of many functions such as pain perception, cardiovascular, respiratory, gastrointestinal, exercise, behavior, endocrine and immunity through binding to G protein-coupled μ opioid receptors, but its main role is Potent analgesic activity, can produce analgesic effect comparable to that of morphine with less side effects, especially they also show obvious analgesic activity in animal models of neuralgia. Because EM-1 has better therapeutic properties than EM-2, such as the separation of rewarding ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K5/107C07K7/06A61K31/07A61K38/08A61P25/04
CPCY02P20/55
Inventor 王锐刘红美刘雪锋
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products